Literature DB >> 12904965

Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats.

Abdeslam Chagraoui1, Philippe Protais, Thierry Filloux, Elisabeth Mocaër.   

Abstract

Agomelatine, an antidepressant with melatonin agonist and 5-HT(2C) antagonist properties, as well as two of its main metabolites, S 21517 (N-[2-(7-hydroxy-1-naphtyl)ethyl]acetamide) and S21540 (N-[2-(3-hydroxy-7-methoxynaphtalen-1-yl)ethyl]acetamide), have been assessed in vitro on pig choroid plexus preparations to determine their affinities for 5-HT(2C) receptors and their effects on inositol phosphate production. These compounds were also tested for their ability to inhibit the penile erections induced by the 5-HT(2C) receptor agonists, m-(chlorophenyl)piperazine (mCPP, 0.75 mg/kg, SC) and Ro 60-0175 (2.5 mg/kg, SC) in Wistar rats. These in vivo effects were compared to those of melatonin and the 5-HT antagonists pizotifen and SB 206,553. Agomelatine and S 21517 had moderate affinity for 5-HT(2C) receptors and behaved in vitro as weak antagonists at this receptor subtype. S 21540 had a 10-fold lower affinity. Pizotifen and SB 206,553 antagonized mCPP- and Ro 60-0175-induced penile erections, suggesting that penile erections induced by mCPP or Ro 60-0175 resulted from the stimulation of 5-HT(2C) receptors. Whereas increasing doses (from 1.25 to 40 mg/kg, IP) of melatonin were unable to modify the penile erections induced by mCPP and Ro 60-0175, agomelatine (from 1.25 to 40 mg/kg, IP) dose-dependently decreased mCPP- as well Ro 60-0175-induced penile erections. Furthermore, increasing doses (from 1.25 to 40 mg/kg, IP) of S 21517 and S 21540, the two main metabolites of agomelatine, did not affect the penile erections induced by mCPP and Ro 60-0175. Considering the similar activity of melatonin and agomelatine at melatonin receptors, these data suggested that the reported effects were not due to the stimulation of melatonin receptors and that, contrary to melatonin, agomelatine exerted 5-HT(2C) receptor antagonist properties in addition to its agonist activity at melatonin receptors. Finally, neither S 21517 nor S 21540 seemed to participate to the observed inhibition of penile erections by agomelatine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904965     DOI: 10.1007/s00213-003-1465-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.

Authors:  J R Martin; M Bös; F Jenck; J Moreau; V Mutel; A J Sleight; J Wichmann; J S Andrews; H H Berendsen; C L Broekkamp; G S Ruigt; C Köhler; A M Delft
Journal:  J Pharmacol Exp Ther       Date:  1998-08       Impact factor: 4.030

Review 2.  A proposed new nomenclature for 5-HT receptors.

Authors:  P P Humphrey; P Hartig; D Hoyer
Journal:  Trends Pharmacol Sci       Date:  1993-06       Impact factor: 14.819

3.  Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters.

Authors:  O Van Reeth; E Olivares; Y Zhang; P C Zee; E Mocaer; R Defrance; F W Turek
Journal:  Brain Res       Date:  1997-07-11       Impact factor: 3.252

4.  In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.

Authors:  G A Kennett; M D Wood; F Bright; J Cilia; D C Piper; T Gager; D Thomas; G S Baxter; I T Forbes; P Ham; T P Blackburn
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

5.  5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. A pharmacological characterization.

Authors:  D Hoyer; C Waeber; P Schoeffter; J M Palacios; A Dravid
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-03       Impact factor: 3.000

6.  Psychotropic effects of ritanserin, a selective S2 antagonist: an open study.

Authors:  W H Strauss; E Klieser
Journal:  Eur Neuropsychopharmacol       Date:  1991-05       Impact factor: 4.600

7.  Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus.

Authors:  O Van Reeth; L Weibel; E Olivares; S Maccari; E Mocaer; F W Turek
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-05       Impact factor: 3.619

8.  Melatonin analogues as agonists and antagonists in the circadian system and other brain areas.

Authors:  S W Ying; B Rusak; P Delagrange; E Mocaer; P Renard; B Guardiola-Lemaitre
Journal:  Eur J Pharmacol       Date:  1996-01-18       Impact factor: 4.432

9.  Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).

Authors:  S M Armstrong; O M McNulty; B Guardiola-Lemaitre; J R Redman
Journal:  Pharmacol Biochem Behav       Date:  1993-09       Impact factor: 3.533

10.  Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.

Authors:  H Lôo; A Hale; H D'haenen
Journal:  Int Clin Psychopharmacol       Date:  2002-09       Impact factor: 1.659

View more
  9 in total

1.  The effect of agomelatine on 5HT(2C) receptors in humans: a clinically relevant mechanism?

Authors:  Trevor R Norman
Journal:  Psychopharmacology (Berl)       Date:  2012-02-15       Impact factor: 4.530

Review 2.  Depression research: where are we now?

Authors:  Saebom Lee; Jaehoon Jeong; Yongdo Kwak; Sang Ki Park
Journal:  Mol Brain       Date:  2010-03-10       Impact factor: 4.041

3.  Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light.

Authors:  Jana Tchekalarova; Lidia Kortenska; Natasha Ivanova; Milena Atanasova; Pencho Marinov
Journal:  Psychopharmacology (Berl)       Date:  2019-11-13       Impact factor: 4.530

Review 4.  Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.

Authors:  B Guardiola-Lemaitre; C De Bodinat; P Delagrange; M J Millan; C Munoz; E Mocaër
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

5.  Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.

Authors:  Michel Bourin; Elisabeth Mocaër; Roger Porsolt
Journal:  J Psychiatry Neurosci       Date:  2004-03       Impact factor: 6.186

6.  Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats.

Authors:  Florence Loiseau; Claudine Le Bihan; Michel Hamon; Marie-Hélène Thiébot
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

7.  Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures.

Authors:  Carlos Clayton Torres Aguiar; Anália Barbosa Almeida; Paulo Victor Pontes Araújo; Germana Silva Vasconcelos; Edna Maria Camelo Chaves; Otoni Cardoso do Vale; Danielle Silveira Macêdo; Luzia Kalyne Almeida Moreira Leal; Glauce Socorro de Barros Viana; Silvânia Maria Mendes Vasconcelos
Journal:  Cell Mol Neurobiol       Date:  2013-06-26       Impact factor: 5.046

8.  Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.

Authors:  Mark J Millan; Mauricette Brocco; Alain Gobert; Anne Dekeyne
Journal:  Psychopharmacology (Berl)       Date:  2004-07-31       Impact factor: 4.530

9.  Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.

Authors:  Amandine Descamps; Colette Rousset; Mark J Millan; Mark Millan; Michael Spedding; Philippe Delagrange; Raymond Cespuglio
Journal:  Psychopharmacology (Berl)       Date:  2009-04-16       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.